NCT01424163COMPLETEDanonymous

A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects

Sponsor

Source record

Knopp Biosciences

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Related intelligence directories

Indication directory: Amyotrophic Lateral Sclerosis Modality directory: small molecule Target directory: Single dose reduced

Source & freshness

Source record

NCT ID

NCT01424163

Original source

ClinicalTrials.gov

Source last updated

Jun 22, 2021

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01424163

Title

A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects

Sponsor

Knopp Biosciences

Status

COMPLETED

Phase

PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Target normalized

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Interventions

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Public preview

Source record

This is a single and multiple dose, open-label study to evaluate the pharmacokinetics (PK), safety, and tolerability of dexpramipexole administered orally to adult Japanese and Caucasian healthy subjects.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT01424163

Status

COMPLETED

Phase

PHASE1

Sponsor

Knopp Biosciences

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 22, 2021

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01424163

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Intervention

Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.